COMMUNIQUÉS West-GlobeNewswire

Premier Biomedical Pain Relief Products Now Sold Through Okeechobee Discount Drugs
20/02/2018
JACKSON CENTER, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTC:BIEI) announced today they have signed a distribution agreement with Okeechobee Discount Drugs to sell and distribute Premier’s pain [...]
CAR T-Cell Therapy Platform
20/02/2018
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing [...]
Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology
20/02/2018
REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated [...]
IRIDEX to Report Fourth Quarter and 2017 Financial Results on March 8, 2018
20/02/2018
MOUNTAIN VIEW, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX ) today announced the Company will release financial results for the fourth quarter and full year 2017 after the close of trading [...]
Easton Pharmaceuticals Announces Key Management Addition With the Appointment of Dr. Daniel Bagi, M.D. to the Board of Directors; Provides Other Updates
20/02/2018
TORONTO, ON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals (OTC:EAPH) announces the appointment of Dr. Daniel Bagi, MD as Director, President of Business Development. Provides other updates: Dr. Daniel Bagi [...]
OPS Code Established for Peripheral Vascular OCT Imaging in Germany
20/02/2018
REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR ), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that the German Institute for Medical [...]
Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
20/02/2018
Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of Initiating Phase III Study REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO ), a [...]
Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent
20/02/2018
BRIDGEWATER, N.J., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the United [...]
VitalHub Selected to Showcase WellLinc Solution Among 40,000 International Attendees at HIMSS 2018
20/02/2018
TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV:VHI) has been selected to present its proprietary “WellLinc” EHR interoperability solution at HIMSS 2018. The Healthcare [...]
Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
20/02/2018
Actimab-MDS to be featured in a Product Theater on February 21 st Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s [...]
Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
20/02/2018
PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and [...]
NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer
20/02/2018
SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for prostate cancer [...]
Horizon Discovery Group plc: Capital Markets Day Date Change to 5 March 2018
20/02/2018
Horizon Discovery Group plc Capital Markets Day Date Change to 5 March 2018 Cambridge, UK, 20 February 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global leader in gene editing and gene [...]
Horizon Discovery Announces Leadership Changes
20/02/2018
Horizon Discovery Announces Leadership Changes Cambridge, UK, 20 February 2018 : Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company", or "the Group"), a global leader in gene editing and gene modulation [...]
Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
20/02/2018
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ) today announced the Audit Committee has completed its investigation into a purported whistleblower complaint and concluded that the [...]
Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
20/02/2018
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and potentially up to $155 [...]
Blood donors urgently needed to meet patient needs leading up to spring break
20/02/2018
OTTAWA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services has issued an urgent call for Canadians to give blood. More than 35,000 donors are needed by Spring Break to ensure all patients continue to have access [...]
Discovery Point Retreat Offers Drug and Alcohol Rehabilitation in Texas
20/02/2018
WAXAHACHIE, Texas, Feb. 20, 2018 (GLOBE NEWSWIRE) -- In an ongoing effort to help combat the substance abuse epidemic affecting the United States, Niznik Behavioral Health introduces Discovery Point Retreat, a drug and [...]
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20/02/2018
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT ), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today [...]

Pages